- Home
- IDAI vs ALLR Comparison
IDAI vs ALLR Comparison
Compare IDAI & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDAI
- ALLR
- Stock Information
- Founded
- IDAI 2016
- ALLR 2004
- Country
- IDAI United States
- ALLR United States
- Employees
- IDAI N/A
- ALLR N/A
- Industry
- IDAI Computer Software: Prepackaged Software
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- IDAI Technology
- ALLR Health Care
- Exchange
- IDAI Nasdaq
- ALLR Nasdaq
- Market Cap
- IDAI 4.9M
- ALLR 13.3M
- IPO Year
- IDAI N/A
- ALLR N/A
- Fundamental
- Price
- IDAI $2.66
- ALLR $0.99
- Analyst Decision
- IDAI
- ALLR
- Analyst Count
- IDAI 0
- ALLR 0
- Target Price
- IDAI N/A
- ALLR N/A
- AVG Volume (30 Days)
- IDAI 40.1K
- ALLR 473.4K
- Earning Date
- IDAI 08-12-2025
- ALLR 08-04-2025
- Dividend Yield
- IDAI N/A
- ALLR N/A
- EPS Growth
- IDAI N/A
- ALLR N/A
- EPS
- IDAI N/A
- ALLR N/A
- Revenue
- IDAI $3,054,143.00
- ALLR N/A
- Revenue This Year
- IDAI $65.46
- ALLR N/A
- Revenue Next Year
- IDAI $12.00
- ALLR N/A
- P/E Ratio
- IDAI N/A
- ALLR N/A
- Revenue Growth
- IDAI N/A
- ALLR N/A
- 52 Week Low
- IDAI $1.43
- ALLR $0.61
- 52 Week High
- IDAI $18.75
- ALLR $7.45
- Technical
- Relative Strength Index (RSI)
- IDAI 66.87
- ALLR 54.51
- Support Level
- IDAI $1.90
- ALLR $0.80
- Resistance Level
- IDAI $2.62
- ALLR $1.09
- Average True Range (ATR)
- IDAI 0.21
- ALLR 0.07
- MACD
- IDAI 0.05
- ALLR 0.02
- Stochastic Oscillator
- IDAI 96.34
- ALLR 63.03
About IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.